Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease
Udelson J, Dilsizian V, Laham R, Chronos N, Vansant J, Blais M, Galt J, Pike M, Yoshizawa C, Simons M. Therapeutic Angiogenesis With Recombinant Fibroblast Growth Factor-2 Improves Stress and Rest Myocardial Perfusion Abnormalities in Patients With Severe Symptomatic Chronic Coronary Artery Disease. Circulation 2000, 102: 1605-1610. PMID: 11015335, DOI: 10.1161/01.cir.102.14.1605.Peer-Reviewed Original ResearchConceptsAdvanced coronary diseaseCoronary diseaseRFGF-2Day 29Myocardial perfusionDay 180Day 57Chronic coronary artery diseaseTherapeutic angiogenesisRest perfusion scoreStress-induced ischemiaCoronary artery diseaseMyocardial perfusion abnormalitiesSingle photon emissionMechanical revascularizationNonstudy patientsArtery diseaseUncontrolled studiesDose groupPerfusion scanPerfusion abnormalitiesReversibility scoreIntravenous administrationPerfusion scoreFactor 2 (Nrf2) proteinTherapeutic Angiogenesis
Simons M, Laham R, Post M, Sellke F. Therapeutic Angiogenesis. BioDrugs 2000, 14: 13-20. PMID: 18034552, DOI: 10.2165/00063030-200014010-00002.Peer-Reviewed Original ResearchGrowth factorTherapeutic angiogenesisAdvanced coronary diseaseAdverse effect profileInitial clinical dataRecent clinical experienceBasic fibroblast growth factorQuality of lifeAngiogenic growth factorsFibroblast growth factorCoronary diseaseEffect profileClinical dataPreclinical studiesAnimal modelsClinical experienceNew vasculatureClinical applicationPractical clinical applicationsAngiogenesisBFGFBasic biologyPatientsFactorsSymptoms